Success Metrics

Active Trials
5(83%)

Phase Distribution

Ph phase_2
2
33%
Ph phase_1
2
33%
Ph phase_3
2
33%

Phase Distribution

2

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

6

all time

Status Distribution
Active(6)

Detailed Status

Recruiting5
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
5
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 22 (33.3%)
Phase 32 (33.3%)

Trials by Status

not_yet_recruiting117%
recruiting583%

Recent Activity

5 active trials
Showing 5 of 6
recruitingphase_1

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

NCT05458219
not_yet_recruitingphase_2

IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer

NCT07415525
recruitingphase_2

IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer

NCT06770439
recruitingphase_3

A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma

NCT06238843
recruitingphase_3

A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)

NCT07066098
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05458219Phase 1

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Recruiting
NCT07415525Phase 2

IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer

Not Yet Recruiting
NCT06770439Phase 2

IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer

Recruiting
NCT06238843Phase 3

A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting
NCT07066098Phase 3

A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)

Recruiting
NCT07025889Phase 1

IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer

Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6